Evotec stock trades close to multi-year lows as Q1 2026 loss weighs on outlook
Published on 08/29/2026 at 07:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE (ISIN DE0005664809) stock continues to struggle in late August 2026, with the shares only slightly above multi-year lows as investors digest the company’s Q1 2026 loss and negative profit margin. As of August 28, 2026, Evotec traded in a narrow range around EUR 3.35 on Xetra, leaving the market value muted despite a triple-digit million euro revenue base in the latest reported quarter.
Evotec shares hover close to ten-year low
Recent trading data on August 28, 2026 showed Evotec stock closing at EUR 3.348 on the German Xetra market, after moving between EUR 3.332 and EUR 3.414 during the session, while the 52-week range stands between EUR 3.176 and EUR 7.300. A same-day German market report noted intraday levels around EUR 3.40 to EUR 3.41, meaning the current price is only modestly above the lower end of the recent trading band and not far from a ten-year low near EUR 3.19 recorded in mid-July 2026. The narrow gap of roughly EUR 0.17 between that low around EUR 3.19 and the recent EUR 3.36 area underlines how little room for error investors currently assign to the stock.
With the share price compressed, the stock’s position relative to its 52-week range has become a key reference point for investors. Trading just above the EUR 3.176 one-year low and well below the EUR 7.300 one-year high, Evotec stock is pricing in significant execution risk and a slow recovery path despite the company’s role as a partner for global pharmaceutical groups. In this context, upcoming earnings updates and any strategic announcements could have an outsized influence on sentiment, given the technically exposed starting point.
Q1 2026 numbers highlight loss and negative margin
The latest available fundamental snapshot for Evotec covers Q1 2026. According to a current earnings overview for the stock, Evotec generated Q1 2026 revenue of EUR 156.64 million, while posting a Q1 2026 net loss of EUR 121.94 million, equivalent to a profit margin of negative 77.84 percent. This means that for each euro of revenue in that quarter, the company lost more than three-quarters of a euro at the bottom line, underscoring the scale of the profitability challenge despite ongoing top-line activity.
The same overview also shows a history of weak earnings leading into 2026. For example, Q3 and Q4 2025 results are reflected as loss-making periods, followed by the negative Q1 2026 margin of 77.84 percent. In other words, the company has now reported several consecutive quarters in which revenue failed to translate into positive net income, a pattern that helps explain why the stock’s valuation has compressed toward the low end of its multi-year range. While some of these losses can be linked to investments and one-off items, the headline figures still dominate perception.
Consensus data embedded in the same earnings dashboard point to expectations for another loss in the next reported period, with a Q3 FY25 earnings estimate of negative EUR 0.13 per share compared with an actual result of negative EUR 0.24 per share in that earlier quarter. This comparison illustrates that, in the past, Evotec has undershot an already cautious earnings forecast by EUR 0.11 per share, reinforcing the perception that turning estimates into reality has been difficult. As long as this gap between forecast and delivery persists, it will be challenging for the company to rebuild investor confidence.
Analyst targets and recommendations remain supportive but tested
Even at depressed price levels, the same market data compilation indicates that the average analyst price target for Evotec currently stands at EUR 4.59, with the lowest target at EUR 3.50 and the highest at EUR 10.00, versus the late August 2026 price of EUR 3.348. On this basis, the average target implies potential upside of roughly EUR 1.24 per share from the current level, or a double-digit percentage gain if the company can execute on its plans. The lower bound of analyst targets, EUR 3.50, still lies slightly above the most recent closing price, which suggests that even cautious analysts do not forecast sustained trading below the current band.
Recommendation data in the same overview show a structure ranging from Strong Buy to Sell, with a visible skew toward more positive ratings at present. This split reflects the market’s debate: some investors focus on Evotec’s position as a drug discovery and development partner that could benefit from long-term outsourcing trends, while others stress the extended loss profile and the negative 77.84 percent profit margin recorded in Q1 2026. The coexistence of supportive targets with a depressed share price illustrates how strongly execution and timing risk influence Evotec’s equity story heading into the next few quarters.
Discovery alliances remain core to Evotec’s business model
Evotec’s operational model is built around discovering and developing new therapeutics on behalf of and in partnership with larger pharmaceutical and biotechnology companies. The company operates platforms that span early discovery, preclinical development, and selected clinical-stage capabilities, aiming to improve the efficiency and success rate of drug projects. In return, Evotec typically receives a mix of research payments, milestones, and potential royalties tied to partnered assets progressing through the pipeline.
One representative offering is its integrated discovery platform, which combines high-throughput screening, medicinal chemistry, biology, and data analytics to identify and optimize candidate molecules for partners. By integrating these functions, Evotec seeks to shorten cycle times and increase the probability that a candidate will reach later stages of development, thereby generating additional milestones over time. For investors, the attractiveness of this model lies in the potential for a growing stream of partner-funded R&D and success-based payments, even though the associated cost structure and long timelines help explain the current stretch of negative margins.
Evotec stock valuation reflects loss profile and execution risk
Against this backdrop of Q1 2026 losses, compressed margins, and cautious forecasts, Evotec stock’s late August 2026 level around EUR 3.35 encapsulates the market’s wait-and-see stance. Trading close to the EUR 3.176 one-year low and far below the EUR 7.300 one-year high, the share price embeds significant skepticism that near-term quarters will deliver a decisive earnings turnaround. At the same time, the presence of an average analyst price target of EUR 4.59 versus the current EUR 3.348 suggests that some upside is conceivable if the company can narrow its losses and demonstrate more stable margins in the next set of reported figures.
As of the August 28, 2026 Xetra close, Evotec remains listed primarily in Frankfurt, with its trading history in 2025 and early 2026 marked by sustained volatility around negative newsflow and disappointing earnings. For now, the Q1 2026 numbers and the negative 77.84 percent margin act as the key reference points for valuation, and upcoming earnings dates later in 2026 are likely to determine whether the stock can move away from multi-year lows or whether the tight gap to levels near EUR 3.19 will be tested again.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT
Exchange: Xetra (Frankfurt)
Price (as of August 28, 2026, 5:38 p.m. local time): EUR 3.348
52-week range: EUR 3.176 - EUR 7.300
Recent reporting: Q1 2026 revenue EUR 156.64 million, net loss EUR 121.94 million, profit margin -77.84 percent
